Outpatient removal of low-grade noninvasive bladder tumor with laser as good as TUR in GA, study says
Denmark: Outpatient tumor removal with laser is as good as transurethral resection in general anesthesia and less burdensome to patients for the removal of recurrent low-grade Ta bladder tumor (BT), claims a recent study in European Urology.
The study further showed that patients who underwent laser photocoagulation of bladder tumors (PC-BT) experienced a better postoperative quality of life, and the frequency of minor complications was lower.
Transurethral resection (TUR) of recurrent low-grade intermediate-risk Ta bladder tumor (BT) is burdensome to patients and the health care system in general anesthesia (GA). In office-based settings, laser technologies enable treatment, reducing morbidity and costs. Considering this, Gyrithe Lynghøj Pedersen, Department of Urology, Herlev-Gentofte Hospital, Capital Region of Denmark, Denmark, and colleagues performed a prospective randomized noninferiority trial comparing 4-months recurrence-free survival following outpatient department (OPD) diode laser coagulation of bladder tumor in local anesthesia and gold standard transurethral resection of BT (TUR-BT) in general anesthesia in intermediate-risk Ta low-grade BT, and to evaluate treatment-related morbidity.
The trial was performed in the Capital Region of Denmark from 2016 to 2020. Patients with verified Ta low-grade BT recurrence were included. Randomization was done on 206 patients; 176 finished treatment and follow-up per protocol.
Comparisons were made between laser photocoagulation of bladder tumor (PC-BT) in OPD using a 980 nm diode laser and gold standard TUR-BT in GA. Both were performed with photodynamic diagnosis (PDD) guidance.
The researchers assessed four-month recurrence-free survival; the predefined inferiority criterion was set at 15%. Pain during PC-BT, postoperative complications, postoperative morbidity, and patient preference were the secondary outcomes.
The study's key findings were as follows:
· After PC-BT, four-month recurrence-free survival was 8% higher. The predefined noninferiority criterion was met.
· Pain score (1–10) during PC-BT was 2.4.
· In the transurethral resection of the bladder group, the postoperative lower urinary tract symptom score (0–100) was 13.9 points higher.
· Following TUR-BT, the frequency of minor complications was 8.1% higher after TUR-BT.
· Of the patients, 98% preferred PC-BT.
"For the removal of recurrent low-grade Ta bladder tumors, PDD-guided PC-BT in OPD is as good as TUR-BT in GA," the researchers wrote. "After PC-BT, postoperative quality of life is better, and the frequency of minor complications was lower."
Reference:
Pedersen GL, Erikson MS, Mogensen K, Rosthøj S, Hermann GG. Outpatient Photodynamic Diagnosis-guided Laser Destruction of Bladder Tumors Is as Good as Conventional Inpatient Photodynamic Diagnosis-guided Transurethral Tumor Resection in Patients with Recurrent Intermediate-risk Low-grade Ta Bladder Tumors. A Prospective Randomized Noninferiority Clinical Trial. Eur Urol. 2022 Sep 1:S0302-2838(22)02564-7. doi: 10.1016/j.eururo.2022.08.012. Epub ahead of print. PMID: 36058804.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.